

Appendix 2 (as supplied by the authors): Brief description of included clinical trials

Author, year	Country	Type of tumour	Chemo on study	Sample	ESA type, weekly dose	Baseline mean Hb (g/dL)
Aapro ⁵³ 2008	Global	Solid	Non-plat	463	Beta 30,000 U	11.3
Gordon ⁶⁴ 2008	USA	Mixed	None	218	Darbe 1.7 µg/kg	10.1
Smith ⁶⁵ 2008	Global	Mixed	None	989	Darbe 1.7 µg/kg	9.5
Strauss ⁵⁴ 2008	Germany	Solid	Plat & radiotherapy	74	Beta 450 U/kg	11.5
Thomas ⁵⁵ 2008	NA, Netherlands	Solid	Plat & radiotherapy	109	Alpha 40,000 U	-
Anon ⁶⁰ 2007	Global	Solid	Plat & etoposide	549	Darbe 300 µg	11.9
Charu ⁶¹ 2007	USA	Mixed	None	287	Darbe 1.5 µg/kg	10.1
Kotasek ⁶² 2007	Global	Mixed	Yes	727	Darbe 2.25; 4.5 µg/kg	9.6
Machtay ⁵¹ 2007	NA	Solid	Radiotherapy*	148	Alpha 40,000 U	12.1
Overgaard ⁶³ 2007	Denmark	Solid	Radiotherapy	515	Darbe 150 µg	-
Wright ⁵² 2007	Canada	Solid	Plat & radiotherapy	70	Alpha 40,000 U	10.3
Anon A ⁴⁹ 2006	China	Hematological	Yes	60	Beta 450 U/kg	-
Anon B ⁴⁸ 2006	China	Solid	Plat	121	Beta 450 U/kg	-
Wilkinson ⁵⁰ 2006	Europe	Solid	Plat, plat/paclitaxel	182	Alpha 30,000 U	10.7
Chang ⁴³ 2005	Canada	Solid	Myelotoxic	354	Alpha 40,000 U	11.3
Christodoulakis ⁴⁴ 2005	Greece	Solid	None	223	Alpha 1050; 2100 U/kg	10.6
Mystakidou ⁴⁵ 2005	Greece	Solid	None	100	Alpha 40,000 U	10.0
O'Shaughnessy ⁴⁶ 2005	USA	Solid	Non-plat	100	Alpha 40,000 U	12.9
Savonije ³ 2005	Netherlands	Solid	Plat	316	Alpha 30,000 U	10.7
Taylor ⁵⁹ 2005	Global	Mixed	Yes	386	Darbe 100 µg	10.0
Witzig ⁴⁷ 2005	USA	Solid	Plat & non-plat	344	Alpha 40,000 U	9.6
Bamias ³⁶ 2003	Greece	Solid	Plat	144	Alpha 30,000 U	11.5
Boogaerts ³⁷ 2003	Europe, SA	Mixed	Yes	262	Beta 450 U/kg	9.1
Hedenus ³⁷ 2003	Global	Hematological	Yes	349	Darbe 2.25 µg/kg	9.5
Henke ³⁸ 2003	Europe	Solid	Radiotherapy	351	Beta 900 U/kg	11.7
Iconomou ³⁹ 2003	Greece	Solid	Plat & non-plat	122	Alpha 30,000 U	10.1
Janinis ⁴⁰ 2003	Greece	Solid	Plat & non-plat	372	Alpha 30,000 U	10.5
Kosmadakis ⁴¹ 2003	Greece	Solid	None	75	Alpha 2100 U/kg	10.9
Kotasek ⁵⁸ 2003	Global	Solid	Yes	249	Darbe 1.3; 2.25; 3.0; 4.0; 4.5; 5.0 µg/kg	9.9
Recasens ⁴² 2003	Spain	Hematological	-	91	Alpha 30,000 U	-
Huddart ³² 2002	UK	Solid	Plat	90	Alpha 30,000 U	-
Osterborg ³³ 2002	Russia, Europe	Hematological	Yes	349	Beta 450 U/kg	9.3
Pronzato ³⁴ 2002	Europe	Solid	Yes	178	Alpha 30,000 – 60,000 U	10.8
Thomas ³⁵ 2002	UK	-	Yes	130	Alpha 30,000 U	10.6
Vansteenkiste ⁵⁶ 2002	Global	Solid	Plat	320	Darbe 2.25 µg/kg	10.1
Dammacco ³⁰ 2001	Europe, Israel	Hematological	Non-plat	145	Alpha 450 U/kg	9.5
Littlewood ³¹ 2001	Europe, SA	Mixed	Non-plat	375	Alpha 450 U/kg	9.8
Qvist ²⁹ 1999	Denmark	Solid	None	100	Alpha 1050 U/kg	12.2
Anon ²³ 1998	-	Mixed	Plat & non-plat	201	Alpha 450 U/kg	-
Dammacco ²⁴ 1998	Italy	Hematological	Non-plat	71	Alpha 450 U/kg	7.9
Ferrini ²⁵ 1998	Italy	Hematological	None	87	Alpha 1050 U/kg	-
Kettelhack ²⁶ 1998	Germany	Solid	None	109	Beta 140,000 U	11.8
Oberhoff ²⁷ 1998	Europe	Solid	Plat & non-plat	227	Beta 35,000 U	9.9
ten Bokkel Huinink ²⁸ 1998	Germany, Netherlands	Solid	Plat	122	Beta 450; 900 U/kg	12.0
Osterborg ²¹ 1996	Europe	Hematological	Non-plat	144	Beta 14,000; 70,000 U	8.0
Park ²² 1996	Korea	Solid	Yes	90	Alpha 450 U/kg	-
Cazzola ²⁰ 1995	Europe	Hematological	Yes	146	Beta 7,000; 14,000; 35,000; 70,000 U	9.4
Cascinu ¹⁸ 1994	Italy	Solid	Plat	100	Alpha 300 U/kg	8.7
Rose ¹⁹ 1994	USA	Hematological	PRN	221	Alpha 450 U/kg	9.4
Abels ¹⁷ 1993 A	USA	Mixed	None	124	Alpha 300 U/kg	-
Abels ¹⁷ 1993 B	USA	Mixed	Non-plat	157	Alpha 450 U/kg	-
Abels ¹⁷ 1993 C	USA	Mixed	Plat	132	Alpha 450 U/kg	-

Note: ESA = erythropoietic-stimulating agent; USA = United States of America; NA = North America; SA = South Africa; UK = United Kingdom; Anon = anonymous; Hb = hemoglobin; "-" indicates that the value was not reported in the study; NR = study listed as "not reported"; PRN = as necessary; Mixed = solid or hematological; Plat = Platinum, Non-plat = Non-Platinum.

*Concurrent chemoradiotherapy options allowed.